FRIEDREICH’S ATAXIA MARKET ANALYSIS

Friedreich’s Ataxia Market, by Drug Class (ACE Inhibitors, Beta Blockers, Diuretics, Para-Benzoquinone, and Others (Vitamin E, Immunomodulators, Skeletal Muscle Relaxants, and Anti-Epileptic Drugs, among others)), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jun 2022
Code : CMI5034
Pages :165
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Friedreich’s Ataxia Market - Restraint

Challenges faced during designing and conducting clinical trials for development of Freidreich's ataxia treatment are the factors that are expected to hinder growth of the global Friedreich’s ataxia market over the forecast period.

Designing clinical trials for rare neurodegenerative diseases such as Friedreich's ataxia is tricky due to the insufficient number of Friedreich's ataxia patients, heterogeneous nature of the disease with a slow and variable progression rate, which makes it difficult to identify reliable outcome measures to monitor the progression of Friedreich's ataxia.

For instance, according to an article published by the Orphanet Journal of Rare Diseases, in August 2020, Friedreich's ataxia is a genetic, neurodegenerative movement disorder, with a typical age of onset (the age at which the symptoms of a disease first appear) between 10 and 15 years. Thus, the diagnosis of the disease takes a long time since its initial stage. The same source also estimated that the average time taken for the diagnosis of rare disorders such as Friedreich's ataxia is 5 years.